Active Filter(s):
Details:
Under the terms of the agreement, Hyloris acquires the worldwide license to all intellectual property rights, and technical proprietary information in relation to the IV formulation technology to develop intravenous acetylsalicylic acid (HY-073) in multiple indications.
Lead Product(s): Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HY-073
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: $0.7 million
Deal Type: Licensing Agreement October 13, 2021